๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 13 Beijing 13 Hangzhou 10 Guangzhou 9 Nanjing 5
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai13 Beijing13 Hangzhou10 Guangzhou9 Nanjing5
All 24 locations
Target enrolment
to

Trials with a site in Shanghai

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07601737Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer, Neoadjuvant Therapy
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
182
Shanghai
2026-04-20
Recruiting
Digital Mind-Body Therapy for Neoadjuvant Breast Cancer
NCT07541664Neoadjuvant Therapy
Fudan University
Not applicable
66
Shanghai
2026-03-25
Not yet open
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
NCT07156604NSCLC, Neoadjuvant Therapy
Fudan University
Phase 2
30
Shanghai
2025-09-30
Not yet open
Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
NCT07169864Breast Cancer, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neoadjuvant Therapy
Jinsong Lu
Not applicable
44
Shanghai
2025-09-15
Recruiting
Sleeve Lobectomy Following Neoadjuvant Therapy in NSCLC
NCT07135856Lung Cancer, Neoadjuvant Therapy
Shanghai Chest Hospital
Observational
400
Shanghai
2025-09-01
Recruiting
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
NCT07150949Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
138
Shanghai
2025-08-28
Not yet open
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
NCT07142863Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy, PD-L1 Antibody
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2
23
Shanghai
2025-08-25
Active, closed
Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial
NCT07492225Neoadjuvant Therapy, Urothelial Carcinoma Ureter, Upper Urinary Tract Urothelial Carcinoma
Changhai Hospital
Phase 2
120
Shanghai
2025-08-15
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
Neoadjuvant SNF Precision Therapy Phase III
NCT06913777Neoadjuvant Therapy
Fudan University
Phase 3
404
Shanghai
2025-04-08
Not yet open
QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer
NCT06404736Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer
Fudan University
Phase 2
73
Shanghai
2024-05-07
Recruiting
CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer
NCT06281405Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Fudan University
Phase 2
192
Shanghai
2024-03-28
Recruiting
Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07266493Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Shanghai Zhongshan Hospital
Phase 2
26
Shanghai
2023-12-01
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

7 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 13 studies
PhaseStudiesRecruitingShare
Phase 29469.2%
Not applicable2115.4%
Observational117.7%
Phase 3117.7%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Fudan University64
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine21
Changhai Hospital10
Jinsong Lu10
Shanghai Chest Hospital11
Shanghai Zhongshan Hospital11
Yang Fan, MD10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.